 |
| |
| Nov-15-19 | Upgrade |
BofA/Merrill |
Neutral → Buy |
$5 → $4 |
|
| May-24-19 | Downgrade |
RBC Capital Mkts |
Outperform → Sector Perform |
$16 → $4.50 |
|
| Nov-16-18 | Resumed |
Piper Jaffray |
Overweight |
$15 |
|
| Aug-08-18 | Resumed |
JP Morgan |
Overweight |
$9 |
|
| Jul-17-18 | Upgrade |
BofA/Merrill |
Underperform → Neutral |
|
|
| Jun-22-18 | Initiated |
Seaport Global Securities |
Neutral |
|
|
| Jan-02-18 | Upgrade |
RBC Capital Mkts |
Sector Perform → Outperform |
|
|
| Dec-20-17 | Initiated |
Barclays |
Equal Weight |
$6 |
|
| Sep-15-17 | Initiated |
RBC Capital Mkts |
Sector Perform |
$6 |
|
| Sep-06-17 | Upgrade |
JP Morgan |
Neutral → Overweight |
|
|
| Sep-06-17 | Upgrade |
Jefferies |
Hold → Buy |
|
|
| Feb-16-17 | Initiated |
Ladenburg Thalmann |
Buy |
$11 |
|
| Aug-12-16 | Upgrade |
Piper Jaffray |
Neutral → Overweight |
|
|
| Aug-04-16 | Downgrade |
JMP Securities |
Mkt Outperform → Mkt Perform |
|
|
| Feb-09-16 | Reiterated |
FBR Capital |
Outperform |
$18 → $6 |
|
| Feb-09-16 | Downgrade |
Needham |
Buy → Hold |
|
|
| Feb-09-16 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
| Feb-09-16 | Downgrade |
Jefferies |
Buy → Hold |
|
|
| Feb-08-16 | Downgrade |
Piper Jaffray |
Overweight → Neutral |
|
|
| Jan-06-16 | Upgrade |
Jefferies |
Hold → Buy |
|
|
|
|
| Apr-03-20 06:04PM | Edited Transcript of BCRX earnings conference call or presentation 5-Mar-20 1:30pm GMT Thomson Reuters StreetEvents |
| 07:07AM | BioCryst Sees Hammer Chart Pattern: Time to Buy? Zacks |
| 07:00AM | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire |
| Apr-02-20 12:28PM | The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore Zacks +5.01% |
| 07:00AM | BioCryst Appoints Anthony Doyle Chief Financial Officer GlobeNewswire |
| Apr-01-20 08:18AM | After a Brutal Q1, Q2 Gives a Ray of Hope: 5 Must Buys Zacks -5.25% |
| Mar-30-20 07:00AM | European Medicines Agency Validates Marketing Authorization Application for Oral, Once-Daily Berotralstat (BCX7353) to Prevent HAE Attacks GlobeNewswire |
| Mar-17-20 06:41AM | Here's Why BioCryst Pharmaceuticals (NASDAQ:BCRX) Can Manage Its Debt Despite Losing Money Simply Wall St. |
| Mar-16-20 07:10AM | BEROTRALSTAT (BCX7353) SIGNIFICANTLY REDUCED USE OF ACUTE ON-DEMAND MEDICINE IN HAE PATIENTS IN APEX-2 GlobeNewswire -20.81% |
| Mar-13-20 02:30PM | 7 Great Stocks for a Small Budget Zacks +9.41% |
| 07:12AM | Cover Story: Triangle life sciences gasping for capital, leaders American City Business Journals |
| Mar-10-20 12:00PM | BioCryst (BCRX) Upgraded to Strong Buy: Here's Why Zacks -10.79% |
| 09:53AM | Implied Volatility Surging for BioCryst (BCRX) Stock Options Zacks |
| Mar-09-20 08:03AM | The Dow, and Crude-Oil Prices, Are Plummeting. Some Biotechs Are in the Green. Barrons.com -23.36% |
| 07:41AM | Top Ranked Momentum Stocks to Buy for March 9th Zacks |
| Mar-05-20 08:25AM | BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates Zacks +9.12% |
| 07:05AM | BioCryst Reports Fourth Quarter and Full Year 2019 Financial Results and Upcoming Key Milestones GlobeNewswire |
| 07:00AM | BioCryst Begins Proof of Concept Trial in PNH Patients With Oral Factor D Inhibitor, BCX9930 GlobeNewswire |
| Mar-03-20 07:00AM | BioCryst to Present at Barclays Global Healthcare Conference GlobeNewswire |
| Mar-02-20 04:15PM | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire +8.67% |
| Feb-28-20 09:30AM | BioCryst Pharmaceuticals (BCRX) in Focus: Stock Moves 8.5% Higher Zacks +9.29% |
| Feb-27-20 12:30PM | Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know Zacks +8.50% |
| 07:00AM | BioCryst to Present New Data at American Academy of Allergy, Asthma & Immunology Annual Meeting GlobeNewswire |
| Feb-25-20 03:25PM | 18 Medical Stocks To Watch Amid The Coronavirus Outbreak Benzinga -5.82% |
| 07:00AM | BioCryst Appoints Alan G. Levin to Board of Directors GlobeNewswire |
| Feb-20-20 07:00AM | BioCryst to Report Fourth Quarter and Full Year 2019 Financial Results on March 5 GlobeNewswire |
| Feb-18-20 07:00AM | FDA Accepts BioCrysts NDA for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks GlobeNewswire |
| Feb-10-20 06:25AM | How Many BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Did Insiders Buy, In The Last Year? Simply Wall St. |
| Feb-06-20 07:00AM | BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire |
| Feb-05-20 11:52AM | Steven Cohen Renews His Interest in Verastem GuruFocus.com |
| Feb-03-20 07:00AM | BioCryst Submits Japanese New Drug Application for Oral, Once Daily Berotralstat GlobeNewswire +10.53% |
| Jan-23-20 01:02PM | 13 Coronavirus-Related Stocks To Watch Amid Wuhan Outbreak Benzinga |
| Jan-15-20 07:00AM | BioCryst Strengthens Commercial Rare Disease Leadership GlobeNewswire |
| Jan-10-20 08:54AM | Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock? Zacks |
| Jan-06-20 07:00AM | BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) GlobeNewswire |
| Jan-03-20 07:00AM | BioCryst to Present at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire |
| Dec-31-19 03:15PM | The ups and downs for stocks of Triangle drugmakers in 2019 American City Business Journals +7.14% |
| Dec-12-19 02:34PM | BioCryst Submits NDA for Hereditary Angioedema Candidate Zacks +7.25% |
| Dec-11-19 03:04PM | BioCryst seeks federal approval for its lead drug candidate American City Business Journals |
| 12:16PM | Here is What Hedge Funds Think About BioCryst Pharmaceuticals, Inc. (BCRX) Insider Monkey |
| 07:00AM | BioCryst Submits New Drug Application for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks GlobeNewswire |
| Dec-04-19 10:02AM | Implied Volatility Surging for BioCryst (BCRX) Stock Options Zacks |
| 07:00AM | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire |
| Nov-21-19 07:49AM | Edited Transcript of BCRX earnings conference call or presentation 6-Nov-19 1:00pm GMT Thomson Reuters StreetEvents +6.16% |
| Nov-20-19 02:18PM | BioCryst locks down another $20M on heels of public offering American City Business Journals |
| Nov-18-19 04:01PM | BioCryst Announces Full Exercise of Underwriters Option to Purchase Additional Shares and Completion of Public Offering of Common Stock GlobeNewswire |
| Nov-15-19 01:38PM | Bank Of America Upgrades BioCryst As Financing Overhang Lifts Partially Benzinga +10.41% |
| 10:09AM | The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval Benzinga |
| Nov-14-19 04:01PM | BioCryst to Present at Upcoming Investor Conferences GlobeNewswire |
| 02:28PM | Durham company sets stage for $55 million offering American City Business Journals |
| Nov-13-19 07:10PM | BioCryst Prices Public Offering of Common Stock GlobeNewswire -10.61% |
| Nov-12-19 04:01PM | BioCryst Commences Public Offering of Common Stock GlobeNewswire -6.28% |
| Nov-11-19 07:45AM | Imagine Owning BioCryst Pharmaceuticals (NASDAQ:BCRX) And Trying To Stomach The 80% Share Price Drop Simply Wall St. -5.91% |
| Nov-07-19 07:00AM | Biocryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology GlobeNewswire |
| Nov-06-19 08:25AM | BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Lags Revenue Estimates Zacks |
| 07:36AM | Triangle pharma inks $44M Japanese deal for new drug American City Business Journals |
| 07:00AM | BioCryst Reports Third Quarter 2019 Financial Results and Upcoming Key Milestones GlobeNewswire |
| 06:55AM | New Clinical Trial Results and Market Research Support Significant Commercial Opportunity for Oral, Once Daily BCX7353 in HAE GlobeNewswire |
| Nov-05-19 06:53AM | The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment Benzinga -6.02% |
| 01:05AM | BioCryst Announces Partnership With Torii Pharmaceutical to Commercialize BCX7353 in Japan for the Prevention of HAE Attacks GlobeNewswire |
| Nov-04-19 07:00AM | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire |
| Nov-01-19 10:03AM | Baker Brothers Make $1.4 Billion in Two Weeks on Biotech Bloomberg |
| 07:00AM | BioCryst Begins Phase 1 Trial With BCX9250, an Oral ALK-2 Inhibitor, for Treatment of Fibrodysplasia Ossificans Progressiva GlobeNewswire |
| Oct-31-19 01:51PM | BioCryst Pharmaceuticals, Inc. (BCRX) Are Selling These Hedge Funds Insider Monkey |
| Oct-30-19 10:33AM | Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for Zacks -8.48% |
| Oct-29-19 10:32AM | Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for Zacks -5.74% |
| 07:00AM | BioCryst to Provide Commercial Update and Report Third Quarter 2019 Financial Results on November 6 GlobeNewswire |
| Oct-28-19 06:59AM | BioCryst Reports Data From Phase 1 Trial of BCX9930 and Announces Plans to Advance Program Into Proof of Concept Study in PNH Patients GlobeNewswire |
| Oct-03-19 07:00AM | BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire |
| Sep-26-19 02:41PM | Triangle drugmaker lands $14M purchase from federal government for flu treatment American City Business Journals |
| 07:15AM | U.S. Government Exercises Option for Additonal Rapivab® for Strategic National Stockpile GlobeNewswire |
| Sep-24-19 04:15PM | BioCryst Pharmaceuticals to Present at Cantor Global Healthcare Conference GlobeNewswire |
| Sep-23-19 07:00AM | BioCryst Appoints Helen Thackray, M.D., to Board of Directors GlobeNewswire +12.94% |
| Sep-10-19 07:44AM | Triangle drugmaker looks to rebound with estimated $2 billion global market for new drug American City Business Journals +5.71% |
| Sep-04-19 07:00AM | BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire |
| Sep-03-19 04:15PM | BioCryst to Present at H.C. Wainwright Global Investment Conference GlobeNewswire |
| Aug-13-19 01:27PM | Edited Transcript of BCRX earnings conference call or presentation 6-Aug-19 12:30pm GMT Thomson Reuters StreetEvents +6.79% |
| Aug-06-19 05:23PM | Biocryst Pharmaceuticals Inc (BCRX) Q2 2019 Earnings Call Transcript Motley Fool |
| 09:45AM | BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Lags Revenue Estimates Zacks |
| 07:15AM | BioCryst Reports Second Quarter 2019 Financial Results GlobeNewswire |
| Aug-05-19 07:15AM | BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) GlobeNewswire -7.19% |
| Jul-30-19 10:38AM | Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q2 Earnings Expected to Decline Zacks |
| Jul-23-19 07:15AM | BioCryst to Report Second Quarter 2019 Financial Results on August 6 GlobeNewswire |
| Jul-03-19 07:15AM | BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire |
| Jul-01-19 07:15AM | BioCryst Appoints Megan Sniecinski Chief Business Officer GlobeNewswire |
| Jun-27-19 04:15PM | Biocryst Begins Enrollment of Phase 1 Trial of BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases GlobeNewswire |
| Jun-11-19 08:20PM | Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy? Insider Monkey -5.54% |
| Jun-05-19 11:25AM | Edited Transcript of BCRX earnings conference call or presentation 8-May-19 12:30pm GMT Thomson Reuters StreetEvents |
| Jun-04-19 04:15PM | BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire |
| May-31-19 07:00AM | BioCryst to Present at Upcoming Investor Conferences GlobeNewswire |
| May-30-19 02:03PM | Here's Why BioCryst Pharmaceuticals Is Soaring Today Motley Fool +15.46% |
| May-22-19 07:34AM | The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study Benzinga |
| May-21-19 04:40PM | Why J.C. Penney, Mallinckrodt, and BioCryst Pharmaceuticals Slumped Today Motley Fool -52.91% |
| 02:30PM | In less than six hours today, this Durham company's stock has dropped 50 percent American City Business Journals |
| 01:18PM | Here's Why BioCryst Pharmaceuticals Collapsed Today Motley Fool |
| 10:54AM | BioCryst Trades Sharply Lower Despite Acing Late-Stage Hereditary Angioedema Drug Trial Benzinga |
| 07:00AM | BioCrysts Oral BCX7353 Meets Primary Endpoint in Phase 3 APeX-2 Trial GlobeNewswire |
| May-14-19 08:46AM | Do Options Traders Know Something About BioCryst Pharmaceuticals (BCRX) Stock We Don't? Zacks |
| May-10-19 07:00AM | BioCryst to Present at Bank of America Merrill Lynch Health Care Conference GlobeNewswire |
| May-09-19 04:15PM | BioCryst Completes Phase 1 Clinical Trial of Galidesivir GlobeNewswire |
|
|
|
|
| BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Stonehouse Jon P | President & CEO | Nov 18 | Buy | 1.45 | 50,000 | 72,500 | 778,086 | Nov 18 04:17 PM | | Sniecinski Megan | Chief Business Officer | Nov 18 | Buy | 1.45 | 45,000 | 65,250 | 45,000 | Nov 18 04:16 PM | | LEE KENNETH B JR | Director | Nov 18 | Buy | 1.45 | 5,000 | 7,250 | 15,252 | Nov 18 04:14 PM | | INGRAM ROBERT ALEXANDER | Director | Nov 18 | Buy | 1.45 | 20,000 | 29,000 | 48,088 | Nov 18 04:12 PM | | Hutson Nancy J | Director | Nov 18 | Buy | 1.45 | 10,000 | 14,500 | 53,046 | Nov 18 04:10 PM | | HEGGIE THERESA | Director | Nov 18 | Buy | 1.45 | 5,000 | 7,250 | 6,672 | Nov 18 04:08 PM | | Barnes Alane P | Senior VP, Chief Legal Officer | Nov 18 | Buy | 1.45 | 20,000 | 29,000 | 102,061 | Nov 18 04:05 PM | | Babu Yarlagadda S | Senior VP - Drug Discovery | Nov 18 | Buy | 1.45 | 25,000 | 36,250 | 155,587 | Nov 18 04:03 PM | | ASELAGE STEVE | Director | Nov 18 | Buy | 1.45 | 15,000 | 21,750 | 21,672 | Nov 18 04:01 PM | | ASELAGE STEVE | Director | May 22 | Buy | 3.57 | 3,000 | 10,710 | 5,000 | May 24 04:20 PM | | STAAB THOMAS R II | Senior Vice President and CFO | May 17 | Sale | 7.45 | 2,500 | 18,625 | 125,176 | May 20 04:21 PM | | STAAB THOMAS R II | Senior Vice President and CFO | May 16 | Option Exercise | 1.42 | 4,750 | 6,745 | 134,926 | May 20 04:21 PM | | STAAB THOMAS R II | Senior Vice President and CFO | May 16 | Sale | 7.72 | 7,250 | 55,970 | 127,676 | May 20 04:21 PM | | STAAB THOMAS R II | Senior Vice President and CFO | May 15 | Option Exercise | 1.42 | 4,750 | 6,745 | 137,426 | May 16 04:29 PM | | STAAB THOMAS R II | Senior Vice President and CFO | May 15 | Sale | 7.92 | 7,250 | 57,420 | 130,176 | May 16 04:29 PM | | STAAB THOMAS R II | Senior Vice President and CFO | May 14 | Option Exercise | 1.42 | 4,500 | 6,390 | 137,176 | May 16 04:29 PM | | STAAB THOMAS R II | Senior Vice President and CFO | May 14 | Sale | 7.62 | 4,500 | 34,290 | 132,676 | May 16 04:29 PM | | STAAB THOMAS R II | Senior Vice President and CFO | May 13 | Option Exercise | 5.51 | 9,750 | 53,723 | 142,426 | May 13 04:57 PM | | STAAB THOMAS R II | Senior Vice President and CFO | May 13 | Sale | 7.76 | 9,750 | 75,660 | 132,676 | May 13 04:57 PM | | STAAB THOMAS R II | Senior Vice President and CFO | May 09 | Option Exercise | 5.51 | 9,750 | 53,723 | 142,426 | May 13 04:57 PM | | STAAB THOMAS R II | Senior Vice President and CFO | May 09 | Sale | 7.63 | 9,750 | 74,393 | 132,676 | May 13 04:57 PM | | STAAB THOMAS R II | Senior Vice President and CFO | May 06 | Option Exercise | 5.51 | 9,000 | 49,590 | 141,676 | May 06 04:51 PM | | STAAB THOMAS R II | Senior Vice President and CFO | May 06 | Sale | 7.75 | 9,000 | 69,750 | 132,676 | May 06 04:51 PM | | STAAB THOMAS R II | Senior Vice President and CFO | May 02 | Option Exercise | 5.51 | 7,750 | 42,703 | 140,426 | May 06 04:51 PM | | STAAB THOMAS R II | Senior Vice President and CFO | May 02 | Sale | 7.30 | 7,750 | 56,575 | 132,676 | May 06 04:51 PM |
|
|
|
|
|
|
